In 2023 the FDA placed CJC-1295 in "Category 2" of its interim 503A bulks list, meaning it identified significant safety concerns and did not permit its use in traditional pharmacy compounding
doi:10.1016/j.mad.2003.11.005 Huff T, Mller CS, Otto AM, Netzker R, Hannappel E
While it is difficult to determine the most effective biologic or small molecule in the treatment of scalp psoriasis because of varying differences in outcome measures and lack of head-to-head studies, guselkumab, infliximab, ixekizumab, and brodalumab appear, on average, to have the highest efficacy in the clearance of scalp psoriasis across studies (Table 1)
Additionally, it aids in preventing and treating some forms of lung cancer
CL Answer I have type 2 diabetes
Book Your B12 Injection Appointment Today Ready to experience the benefits of Vitamin B12 injections for weight loss and energy